Transgenic models of TauP301L/S (Santacruz et al., 2005; Yoshiyama et al., 2007) and viral models of TauP301L (Cook et al., 2015; Wegmann et al., 2017) are useful tools to study the progression of tau pathology and investigate factors that could lead to the risk of developing any tauopathy, including AD. This evidence concerns the gene MAPT and Alzheimer disease.